Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
Clinical trial NCT05777278 · RECRUITING
Trial details
- NCT number
- NCT05777278
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-26
- Primary completion
- 2027-08-31
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.